Skip to main content
OpenTrials
Completed

NCT Number: NCT04407156

Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom

Severe Acute respiratory syndrome coronovirus (SARS-CoV-2) was first described in Wuhan in December 2019. It quickly spread to rest of the world and was declared pandemic by World health organisation. Initial case series focused on lung involvement in the form alveolar haemorrhages and respiratory failure. However, subsequently, there have been reports of kidney involvement resulting in severe acute kidney injury. However, the reported incidence from Chinese data has been less than 5% and detailed epidemiology of AKI in COVID-19 disease is lacking.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–110 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Derby Hospital NHS Foundation Trust

Derby, Derbyshire, DE22 3NE, United Kingdom

About this study

On 31st December 2019, a cluster of pneumonia cases were detected in Hubei province of China where the cause was unclear. The cause for these cases was subsequently identified as a virus which was referred to as SARS-CoV-2, and the associated disease as COVID-19.This evolved rapidly into a global pandemic with first case reported in UK as early as on 30th January 2020. As of 30th April 2020, there have been 3.05 million laboratory confirmed cases world-wide with 161,145 cases in United Kingdom (UK) in 539,768 cases tested for COVID-19. The epidemiology of COVID-19 has differed in China, US and Italy which have different demographic characteristics, testing methods and different ways to curb the spread of infection which can be altered by many things, including behaviour, and the stringent social distancing measure.Though the pandemic started in China, as of 30th April 2020, it has reported only 58.32 cases per million people (pmp) as compared to United kingdom which has reported 2433.8 cases pmp. This has resulted in different epidemiology of COVID-19 and organ system involvement. Lung involvement in the form of alveolar haemorrhages and respiratory failure has been well document in patients with COVID-19 and has been focus of attention, however, other organs are also affected in COVID-19, but there has been limited information kidney involvement in COVID patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients who are admitted to the hospital with suspected COVID-19 infection between 1st March 2020 and 8th May 2020 and who meet following criteria will be included

  • Adult patients greater or equal to 18 years of age.
  • Swab results available for SARS CoV-19
  • Patients admitted to the hospital as per the national screening criteria

Exclusion criteria

The following patients will be excluded from the study

  • Paediatric patients as defined by age of <18 years of age
  • Swab results which are awaited
  • Patients on haemodialysis or peritoneal dialysis

Treatment and study plan

Acute Kidney Injury

Other

AKI in COVID positive cases

Primary outcomes

  1. Incidence of Acute kidney injury in COVID-19

    Time frame: 7 days

    This is the proportion of patients with Acute kidney injury in COVID-19

Secondary outcomes

  1. All-cause mortality in AKI patients

    Time frame: 7 days

    This is the number of deaths in COVID-19 AKI patients

Sponsors and collaborators

Lead sponsor

University Hospitals of Derby and Burton NHS Foundation Trust

Other

Registry information

Official study title

Acute Kidney Injury In Corona Virus Infection Disease (COVID19) in United Kingdom

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
May 29, 2020
Registry last updated
Sep 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.